-
Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizures found with DTaP vaccine, new REMS for quinine.
-
A new three-drug antihypertensive pill, combining an angiotensin II receptor antagonist (olmesartan [OLM]), a calcium channel blocker (amlodipine [AML]), and a thiazide diuretic (hydrochlorothiazide [HCTZ]), has been approved by the FDA. The new combination is marketed by Daiichi Sankyo as Tribenzor.
-
Vital exhaustion predicts long-term risk for adverse cardiac events in men and women, independent of established biomedical risk factors.
-
Of late, there has been a renaissance of interest in identification and management of hypogonadism in older men.
-
The FDA has approved the combination of dutasteride (DUT) and tamsulosin (TAM) in a single capsule. Dutasteride is a 5-a reductase inhibitor and tamsulosin is an a-adrenergic antagonist. The combination is marketed by GlaxoSmithKline as Jalyn™.
-
Use of simply obtained historical, physical, and laboratory data can distinguish gout from other forms of arthritis in many patients and avoid joint aspiration.
-
Obstructive sleep apnea is associated with an increased risk of incident heart failure in community-dwelling middle-aged and older men, but not in women.
-
In a large, well-designed observational study of patients with COPD, treatment with β-blockers during a mean follow-up period of 7.2 years was found not only to reduce the risk of exacerbations, but also to improve survival.
-
In this issue: Antiviral drugs and birth defects, bisphosphonates and esophageal cancer, naltrexone plus bupropion for weight loss, 2010-11 influenza vaccine, FDA Actions.
-
The author summarizes the protocols used at his institution to prevent adhesions in patients who were undergoing evaluation and treatment for significant pelvic pathology.